atezolizumab + cyclophosphamide + pegylated liposomal doxorubicin

Atezolizumab + cyclophosphamide + pegylated liposomal doxorubicin is a combination regimen used in oncology, particularly studied for metastatic triple-negative breast cancer (mTNBC). Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Cyclophosphamide is an alkylating agent that interferes with DNA replication and cell division, leading to cytotoxic effects on rapidly dividing cells. Pegylated liposomal doxorubicin is a formulation of the anthracycline antibiotic doxorubicin encapsulated in PEG-coated liposomes, which allows for prolonged circulation time and preferential tumor uptake while reducing cardiotoxicity. The combination aims to leverage the immunomodulatory effects of chemotherapy with the immune activation provided by atezolizumab[1][6][7]. This regimen has been evaluated in clinical trials such as the ALICE trial for mTNBC, showing tolerability and indications of clinical benefit[1].